Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Events

ATOPP

Shorla Oncology Attends ATOPP Summit 2025

July 17th 2025July 9th 2025

Read More

National Oncology Conference Logo

Shorla Oncology Attends 2025 Cardinal Health™ NOC

July 17th 2025June 29th 2025

Read More

ASCO Annual Meeting

Shorla Oncology Participates in ASCO 2025

July 17th 2025May 31st 2025

Read More

PCMA Meeting

Shorla Oncology is attending the PCMA Annual Meeting March 10-11 2025

July 17th 2025March 10th 2025

Read More

Milan

Audrene Rice, Our R&D Pipeline and Portfolio Manager, is attending  Bio-Europe from March 17-19 in Milan, Italy

March 10th 2025

Read More

photo

University City Science Center Bootcamp, Philadelphia, USA

March 7th 2022February 14th 2020

Read More

photo

J.P. Morgan Annual Healthcare Conference, San Francisco, USA

March 7th 2022January 10th 2020

Read More

Photo

American Society of Clinical Oncologists (ASCO) Annual Meeting 2019, Chicago, USA

March 7th 2022June 4th 2019

Read More

MIT

Shorla attending MIT-Harvard Medical School Healthcare Innovation Bootcamp, Boston, USA

April 15th 2021May 7th 2019

Read More

Older posts
Page1 Page2
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

CALIFORNIA COMPLIANCE PROGRAM DECLARATION

Company number: 618033
©SHORLA ONCOLOGY® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.